Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer | MicrobiomeTrials← Back to trialsNCT07199764
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-11-25Est. Completion: 2027-10
Enrollment target: 100 participants Locations- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in
CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)Advanced Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumor…
Orlando, United StatesEst. completion May 2029
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)HR+/HER2- Ductal Breast Cancer (BC)
HR+/HER2- Lobular Breast Cancer (BC)
Triple Negative Breast Cancer (TNBC)
Colorectal Cancer (CRC)
Soft Tissue Sarcoma (STS)
The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokine…
Chuo Ku, JapanEst. completion Jan 14, 2028